Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Axsome Therapeutics ( (AXSM) ) just unveiled an update.
On May 4, 2026, Axsome Therapeutics reported first quarter 2026 net product revenue of $191.2 million, up 57% year over year, driven primarily by AUVELITY sales of $153.2 million and supported by growth in SUNOSI and SYMBRAVO. Despite higher R&D and sharply increased SG&A tied to pre-launch and commercialization activities, the company posted a net loss of $64.5 million and ended the quarter with $305.1 million in cash and equivalents, while stating it expects existing funds to carry operations into cash flow positivity.
Operationally, the quarter was marked by the U.S. FDA’s April 2026 approval of AUVELITY for agitation associated with dementia due to Alzheimer’s disease and the planned June 2026 launch, expansion of AUVELITY and SYMBRAVO sales forces, and strong prescription and payer coverage trends across the portfolio. Axsome also advanced its pipeline by submitting an NDA for AXS-12 in narcolepsy cataplexy, adding Phase 3–ready AXS-20 for schizophrenia and Tourette syndrome, and progressing late-stage solriamfetol and AXS-05 programs, reinforcing its positioning as an emerging leader in CNS therapeutics and signaling potential long-term growth for patients and shareholders.
The most recent analyst rating on (AXSM) stock is a Buy with a $270.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.
Spark’s Take on AXSM Stock
According to Spark, TipRanks’ AI Analyst, AXSM is a Neutral.
The score is held back primarily by weak financial durability—ongoing net losses, negative free cash flow, and elevated leverage. Offsetting this are strong technical uptrend signals and a constructive fundamental outlook from the latest call and corporate catalysts, highlighted by rapid product revenue growth and the FDA approval expanding AUVELITY’s addressable market.
To see Spark’s full report on AXSM stock, click here.
More about Axsome Therapeutics
Axsome Therapeutics, Inc. is a New York-based biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system disorders. Its marketed products include AUVELITY for major depressive disorder and agitation associated with dementia due to Alzheimer’s disease, SUNOSI for excessive daytime sleepiness linked to obstructive sleep apnea or narcolepsy, and SYMBRAVO for the acute treatment of migraine in adults, while its pipeline targets multiple psychiatric and neurological conditions with high unmet need.
Average Trading Volume: 652,178
Technical Sentiment Signal: Buy
Current Market Cap: $10.56B
For a thorough assessment of AXSM stock, go to TipRanks’ Stock Analysis page.